Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Adenine causes cell cycle arrest and autophagy of chronic myelogenous leukemia K562 cells via AMP-activated protein kinase signaling.

Chen SY, Lin CH, Lin JT, Cheng YF, Chen HM, Kao SH.

Oncol Lett. 2017 Nov;14(5):5575-5580. doi: 10.3892/ol.2017.6890. Epub 2017 Sep 6.

2.

Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways.

Kumar A, Bhattacharyya J, Jaganathan BG.

Sci Rep. 2017 Aug 25;7(1):9535. doi: 10.1038/s41598-017-10373-3.

3.

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Patel AB, O'Hare T, Deininger MW.

Hematol Oncol Clin North Am. 2017 Aug;31(4):589-612. doi: 10.1016/j.hoc.2017.04.007. Review.

PMID:
28673390
4.

Real-time quantitative analysis of metabolic flux in live cells using a hyperpolarized micromagnetic resonance spectrometer.

Jeong S, Eskandari R, Park SM, Alvarez J, Tee SS, Weissleder R, Kharas MG, Lee H, Keshari KR.

Sci Adv. 2017 Jun 16;3(6):e1700341. doi: 10.1126/sciadv.1700341. eCollection 2017 Jun.

5.

ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells.

Karvela M, Baquero P, Kuntz EM, Mukhopadhyay A, Mitchell R, Allan EK, Chan E, Kranc KR, Calabretta B, Salomoni P, Gottlieb E, Holyoake TL, Helgason GV.

Autophagy. 2016 Jun 2;12(6):936-48. doi: 10.1080/15548627.2016.1162359. Epub 2016 May 11.

6.

Co-Inhibition of GLUT-1 Expression and the PI3K/Akt Signaling Pathway to Enhance the Radiosensitivity of Laryngeal Carcinoma Xenografts In Vivo.

Luo XM, Xu B, Zhou ML, Bao YY, Zhou SH, Fan J, Lu ZJ.

PLoS One. 2015 Nov 24;10(11):e0143306. doi: 10.1371/journal.pone.0143306. eCollection 2015.

7.

Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model.

Hasan MN, Queudeville M, Trentin L, Eckhoff SM, Bronzini I, Palmi C, Barth T, Cazzaniga G, te Kronnie G, Debatin KM, Meyer LH.

Oncotarget. 2015 Jan 30;6(3):1382-95.

8.

BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.

Morotti A, Panuzzo C, Crivellaro S, Carrà G, Fava C, Guerrasio A, Pandolfi PP, Saglio G.

Cell Cycle. 2015;14(7):973-9. doi: 10.1080/15384101.2015.1006970.

9.

Predicting interactome network perturbations in human cancer: application to gene fusions in acute lymphoblastic leukemia.

Hajingabo LJ, Daakour S, Martin M, Grausenburger R, Panzer-Grümayer R, Dequiedt F, Simonis N, Twizere JC.

Mol Biol Cell. 2014 Dec 1;25(24):3973-85. doi: 10.1091/mbc.E14-06-1038. Epub 2014 Oct 1.

10.

The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.

Gustafsson K, Jamalpour M, Trinh C, Kharas MG, Welsh M.

J Hematol Oncol. 2014 Jun 21;7:45. doi: 10.1186/1756-8722-7-45.

11.

The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.

Pellicano F, Scott MT, Helgason GV, Hopcroft LE, Allan EK, Aspinall-O'Dea M, Copland M, Pierce A, Huntly BJ, Whetton AD, Holyoake TL.

Stem Cells. 2014 Sep;32(9):2324-37. doi: 10.1002/stem.1748.

12.

PIK3CA gene amplification and PI3K p110α protein expression in breast carcinoma.

Firoozinia M, Zareian Jahromi M, Moghadamtousi SZ, Nikzad S, Abdul Kadir H.

Int J Med Sci. 2014 Apr 22;11(6):620-5. doi: 10.7150/ijms.8251. eCollection 2014.

13.

Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.

Ichim CV.

Stem Cells Transl Med. 2014 Apr;3(4):405-15. doi: 10.5966/sctm.2012-0159. Epub 2014 Mar 5. Review.

14.

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T, Ohyashiki K.

Cancer Biol Ther. 2014 Feb;15(2):207-15. doi: 10.4161/cbt.26725. Epub 2013 Nov 8.

15.

Targeting survival pathways in chronic myeloid leukaemia stem cells.

Sinclair A, Latif AL, Holyoake TL.

Br J Pharmacol. 2013 Aug;169(8):1693-707. doi: 10.1111/bph.12183. Review.

16.

Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.

Gillis LC, Berry DM, Minden MD, McGlade CJ, Barber DL.

Leukemia. 2013 Aug;27(8):1666-76. doi: 10.1038/leu.2013.40. Epub 2013 Feb 12.

17.

Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.

Baran Y, Saydam G.

J Blood Med. 2012;3:139-50. doi: 10.2147/JBM.S29132. Epub 2012 Nov 16.

18.

Analyzing gene expression profile in K562 cells exposed to sodium valproate using microarray combined with the connectivity map database.

Zhang XZ, Yin AH, Lin DJ, Zhu XY, Ding Q, Wang CH, Chen YX.

J Biomed Biotechnol. 2012;2012:654291. doi: 10.1155/2012/654291. Epub 2012 Jun 4.

19.

Extensive gene-specific translational reprogramming in a model of B cell differentiation and Abl-dependent transformation.

Bates JG, Salzman J, May D, Garcia PB, Hogan GJ, McIntosh M, Schlissel MS, Brown PO.

PLoS One. 2012;7(5):e37108. doi: 10.1371/journal.pone.0037108. Epub 2012 May 31.

20.

Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro.

Tong Y, Liu YY, You LS, Qian WB.

Acta Pharmacol Sin. 2012 Apr;33(4):542-50. doi: 10.1038/aps.2011.192. Epub 2012 Mar 12.

Supplemental Content

Support Center